Aprepitant + Scopolamine
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nausea
Conditions
Nausea, Vomiting
Trial Timeline
Apr 1, 2008 โ Mar 1, 2010
NCT ID
NCT00659737About Aprepitant + Scopolamine
Aprepitant + Scopolamine is a pre-clinical stage product being developed by Merck for Nausea. The current trial status is completed. This product is registered under clinical trial identifier NCT00659737. Target conditions include Nausea, Vomiting.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00659737 | Pre-clinical | Completed |
| NCT00717054 | Pre-clinical | Completed |
Competing Products
20 competing products in Nausea